Multiple external cervical resorption lesions in patient with graft versus host disease treated with systemic bleomycin. A case report.
The phenomenon of multiple external cervical root resorption (ECRR) lesions in a single patient is rare but may have a link with chemotherapeutic agent Bleomycin. This case details an adult male with multiple ECRR lesions that developed following chemotherapy. His treatment regime for Hodgkin ’s lymphoma included the chemotherapeutic antibiotic Bleomycin, which has previously been linked with development of multiple ECRR lesions. The patient developed graft versus host disease following an allogenic stem cell transplant which could have a significant role in the development and promoti on of the ECRR lesions. (Source: Jo...
Source: Journal of Endodontics - February 2, 2024 Category: Dentistry Authors: Daniel Merrick, Henry F. Duncan, Andrew Bolas, Annie Hughes, Michael O ’Sullivan Tags: Case Report/Clinical Techniques Source Type: research
Cancers, Vol. 16, Pages 649: Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins & rsquo;s Lymphoma Patients & mdash;A Single Centre Experience
Conclusions: By reducing the radiotherapy volume and the doses in the treatment of infradiaphragmatic fields, treatment with significantly fewer acute and long-term side effects is possible. At the same time, efficiency and local disease control are not compromised. (Source: Cancers)
Source: Cancers - February 2, 2024 Category: Cancer & Oncology Authors: Lea Galunic Bilic Fedor Santek Zdravko Mitrovic Sandra Basic-Kinda Dino Dujmovic Marijo Vodanovic Inga Mandac Smoljanovic Slobodanka Ostojic Kolonic Ruzica Galunic Cicak Igor Aurer Tags: Article Source Type: research
Gemcitabine ‐based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes
ConclusionsThe GBM/GBC regimen is effective and well-tolerated, offering outcomes that are highly comparable to those in NHL patients conditioned with BEAM/BEAC, as demonstrated in a prognostically matched cohort. (Source: Cancer Medicine)
Source: Cancer Medicine - February 1, 2024 Category: Cancer & Oncology Authors: Huimin Liu,
Hesong Zou,
Dandan Shan,
Wei Liu,
Wenyang Huang,
Weiwei Sui,
Shuhui Deng,
Tingyu Wang,
Rui Lv,
Mingwei Fu,
Yan Xu,
Shuhua Yi,
Gang An,
Yaozhong Zhao,
Lugui Qiu,
Dehui Zou Tags: RESEARCH ARTICLE Source Type: research
Incidence of Restrictive Lung Disease Following Autologous Stem Cell Transplantation for High Risk Lymphoma
Serial monitoring of pulmonary function tests (PFT) following allogeneic hematopoietic cell transplants (HCT) is common, with both obstructive and restrictive lung defects well described. In contrast, serial monitoring of PFT post autologous HCT is less commonly performed, with the incidence of post-HCT lung disease ill-defined in this population. We now report the incidence of restrictive lung disease (RLD) in a series of autograft recipients undergoing transplantation for Hodgkin's (HL) or non-Hodgkin's lymphoma (NHL) at our center. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Matthew Whalen, Colin Hayes, Thomas Braun, Dawson Myers, John Magenau, John Maciejewski, Sarah Anand, Mary Mansour Riwes, Ghada Abusin, Mark T. Vander Lugt, Monalisa Ghosh, Attaphol Pawarode, Sung Choi, Michael Triebwasser, Gregory A. Yanik Tags: 145 Source Type: research
Retrospective Study Assessing Outcomes of AYA Patients with Lymphoma Following Auto Stem Cell Transplant
Hematopoietic stem cell transplantation (HSCT) offers a potential curative option and can prolong overall survival (OS) for many patients with Hodgkin and non-Hodgkin Lymphomas (NHL). Lymphomas in the adolescent and young adult (AYA) population have had minimal improvement in lymphoma-specific survival rates over the years, especially when compared to pediatric and older populations. AYAs also are at increased risk for treatment/disease related late effects given the likelihood of longer life spans following treatment. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Daniel Charles Stapor, Yuliya Shestovska, Rashmi Khanal, Peter Abdelmessieh, Michael J Styler, Henry Fung, Asya Varshavsky Yanovsky Tags: 498 Source Type: research
Safety and Efficacy of Bridging Radiation Therapy in the Context of CD19 CART Therapy for Non-Hodgkin Lymphoma: Systematic Review and Meta-Analysis
Bridging radiation therapy (BRT) has been increasingly utilized in the context of CD19 chimeric antigen receptor T-cell (CART) therapy for non-Hodgkin lymphoma (NHL) for disease control and palliation while awaiting CART manufacturing. However, the impact on safety and efficacy remains unknown. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Mohammad Alhomoud, Rahma Ibrahim, Zhengming Chen, Jeremie Martinet, Michelle Foley, Alexandra Gomez-Arteaga, Monica L Guzman, Paul Pagnini, Koen van Besien, Tsiporah B. Shore, Samuel Yamshon Tags: 297 Source Type: research
Construction and in Vitro Evaluation of a Novel Anti-CD25 Chimeric Antigen Recepto
The interleukin-2 (IL-2) receptor has been an attractive target to treat hematologic malignancies for decades, in as much as CD25 is expressed on lymphoma or leukemia cells of T- and B-cell origin, including Adult T-cell leukemia/lymphoma, chronic lymphocytic leukemia, cutaneous T-cell lymphoma (CTCL), Hodgkin's disease, as well as B-cell non-Hodgkin's lymphoma. To date, there are no FDA approved chimeric antigen receptor T-cells (CAR-T) that treat T-cell neoplasms, so an effective CAR-T that targets a T-cell neoplasm such as Adult T-cell leukemia/lymphoma, is direly needed. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ira Braunschweig Tags: 225 Source Type: research
Analysis of Notch1 protein expression in methotrexate-associated lymphoproliferative disorders
In this study, to investigate the association of NOTCH1 in the pathogenesis of MTX-LPD, we evaluated protein expression of Notch1 in nuclei immunohistochemically in MTX-LPD cases [histologically DLBCL-type (n = 24) and classical Hodgkin lymphoma (CHL)-type (n = 24)] and de novo lymphoma cases [DLBCL (n = 19) and CHL (n = 15)]. The results showed that among MTX-LPD cases, the expression of Notch1 protein was significantly higher in the DLBCL type than in the CHL type (P < 0.001). In addition, among DLBCL morphology cases, expression of Notch1 tended to be higher in MTX-LPD than in the de novo group; however this differen...
Source: Journal of Clinical and Experimental Hematopathology : JCEH - January 28, 2024 Category: Hematology Authors: Takeshi Okatani Midori Filiz Nishimura Yuria Egusa Sayako Yoshida Yoshito Nishimura Asami Nishikori Tadashi Yoshino Hidetaka Yamamoto Yasuharu Sato Source Type: research
